Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 5/20 | 0.49 |
| ▸ | SLCO1B1 | Q9Y6L6 | 4/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.49 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.49 |
| ▸ | RHOC | P08134 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.49 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.49 |
| ▸ | ABCC3 | O15438 | 2/20 | 0.47 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.47 |
| ▸ | SLCO1B3 | Q9NPD5 | 2/20 | 0.47 |
| ▸ | PDE6D | O43924 | 3/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Calcium SCHEMBL4738406 | 0.99 | HMGCR (0.48) | HMGCRSLCO1B1ABCB11HDAC2HDAC1 | |
| SCHEMBL30668285 | 0.94 | SLCO1B1 (0.49) | HMGCRSLCO1B1ABCB11HDAC2HDAC1 | |
| SCHEMBL30668286 | 0.94 | SLCO1B1 (0.49) | HMGCRSLCO1B1ABCB11HDAC2HDAC1 | |
| SCHEMBL30668287 | 0.94 | SLCO1B1 (0.49) | HMGCRSLCO1B1ABCB11HDAC2HDAC1 | |
| SCHEMBL29804644 | 0.91 | SLCO1B1 (0.51) | HMGCRSLCO1B1ABCB11HDAC2HDAC1 | |
| SCHEMBL7080939 | 0.91 | SLCO1B1 (0.51) | HMGCRSLCO1B1ABCB11HDAC2HDAC1 | |
| SCHEMBL18051134 | 0.91 | HMGCR (0.53) | HMGCRSLCO1B1ABCB11HDAC2HDAC1 | |
| SCHEMBL29795041 | 0.84 | SLCO1B1 (0.51) | HMGCRSLCO1B1ABCB11HDAC2HDAC1 | |
| SCHEMBL6100481 | 0.74 | SLCO1B1 (0.45) | HMGCRSLCO1B1ABCB11HDAC2HDAC1 | |
| SCHEMBL3611017 | 0.74 | HMGCR (0.77) | HMGCRSLCO1B1ABCB11HDAC2HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-3254219-B2 | — | — | 2002-02-04 | — | — | JP | claimed |
| EP-0680320-A1 | STABLE ORAL CI-981 FORMULATION AND PROCESS OF PREPARING SAME | Warner-Lambert Technologies, Inc. (US) | 1995-11-08 | — | — | EP | claimed |
| WO-1994016693-A1 | STABLE ORAL CI-981 FORMULATION AND PROCESS OF PREPARING SAME | WARNER-LAMBERT COMPANY (US) | 1994-08-04 | — | — | WO | claimed |
| CN-116574047-A | Method for preparing atorvastatin calcium | 杭州新曦科技有限公司 | 2023-08-11 | — | — | CN | disclosed |
| EP-4188338-A1 | BILAYER TABLET COMPRISING EZETIMIBE AND ATORVASTATIN | KRKA, d.d., Novo mesto (SI) | 2023-06-07 | — | — | EP | disclosed |
| WO-2022023206-A1 | BILAYER TABLET COMPRISING EZETIMIBE AND ATORVASTATIN | KRKA, D.D., NOVO MESTO (SI) | 2022-02-03 | — | — | WO | disclosed |
| EP-2575757-A1 | WATER SOLUBLE FORMULATION COMPRISING A COMBINATION OF AMLODIPINE AND A STATIN | Bilgic, Mahmut (TR) | 2013-04-10 | — | — | EP | disclosed |
| WO-2009157005-A1 | CRYSTALLINE FORMS OF ATORVASTATIN HEMI-MAGNESIUM SALT AND A PROCESS THEREOF | BIOCON LIMITED (IN) | 2009-12-30 | — | — | WO | disclosed |
| WO-2008075165-A1 | NOVEL PROCESS FOR THE SYNTHESIS OF [R-(R*, R*)]-2-(4-FLUOROPHENYL)-BETA, DELTA-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | PFIZER PRODUCTS INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| EP-1756053-A1 | PROCESS FOR THE PREPARATION OF ATORVASTATIN | Ranbaxy Laboratories Limited (IN) | 2007-02-28 | — | — | EP | disclosed |
| EP-1732886-A1 | POLYMORPHS OF ATORVASTATIN TERT.-BUTYLESTER AND USE AS INTERMEDIATES FOR THE PREPARATION OF ATORVASTATIN | KRKA, tovarna zdravil, d.d., Novo mesto (SI) | 2006-12-20 | — | — | EP | disclosed |
| EP-1562583-A1 | ATORVASTATIN CALCIUM FORM VI OR HYDRATES THEREOF | Morepen Laboratories Ltd. (IN) | 2005-08-17 | — | — | EP | disclosed |
| WO-2005026116-A1 | CRYSTALLINE FORMS OF `R-(R*,R*)]-2-(4-FLUOROPHENYL)-BETA,DELTA-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-`(PHENYLAMINO)CARBONYL!-1H-PYRROLE-1-HEPTANOIC ACID | WARNER-LAMBERT COMPANY LLC (US) | 2005-03-24 | — | — | WO | disclosed |
| CN-1524073-A | ' R- (R, R) -2- (4-fluorophenyl) -beta, delta-dihydroxy-5- (1-methylethyl) -3-phenyl-4- (phenylamino) carbonyl-1H-pyrrole-1-heptanoic acid calcium salt (2: 1) (atorvastatin) | ����-�����ع�˾ | 2004-08-25 | — | — | CN | disclosed |
| WO-2004022053-A1 | ATORVASTATIN CALCIUM FORM VI OR HYDRATES THEREOF | MOREPEN LABORATORIES LIMITED (IN) | 2004-03-18 | — | — | WO | disclosed |
| EP-1353917-A2 | NOVEL PROCESS FOR THE SYNTHESIS OF 5-(4-FLUOROPHENYL)-1-(2-((2R, 4R)-4-HYDROXY -6-OXO-TETRAHYDRO-PYRAN-2-YL)-ETHYL)-2-ISOPROPYL-4-PHENYL-1H-PYRROLE-3-CARBOXYLIC ACID PHENYLAMIDE | WARNER-LAMBERT COMPANY (US) | 2003-10-22 | — | — | EP | disclosed |
| WO-2002055519-A2 | NOVEL PROCESS FOR THE SYNTHESIS OF 5-(4-FLUOROPHENYL)-1-[2-((2R, 4R)-4-HYDROXY -6-OXO-TETRAHYDRO-PYRAN-2-YL)-ETHYL]-2-ISOPROPYL-4-PHENYL-1H-PYRROLE-3-CARBOXYLIC ACID PHENYLAMIDE | WARNER LAMBERT CO (US) | 2002-07-18 | — | — | WO | disclosed |
| EP-0915866-A1 | IMPROVED PROCESS FOR THE SYNTHESIS OF PROTECTED ESTERS OF (S)-3,4-DIHYDROXYBUTYRIC ACID | WARNER-LAMBERT COMPANY (US) | 1999-05-19 | — | — | EP | disclosed |
| WO-1998004543-A1 | IMPROVED PROCESS FOR THE SYNTHESIS OF PROTECTED ESTERS OF (S)-3,4-DIHYDROXYBUTYRIC ACID | WARNER-LAMBERT COMPANY (US) | 1998-02-05 | — | — | WO | disclosed |
| US-5003080-A | Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis | WARNER-LAMBERT COMPANY (US) | 1991-03-26 | — | — | US | disclosed |